The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Durable responses after CD19 CAR-T plus ibrutinib in CLL
Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses responses after CD19-specific CAR T-cell therapy with concurrent ibrutinib in patients with chronic lymphocytic leukemia (CLL) after prior ibrutinib failure. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
